Skip to Content

5,730 Results Found

  • Article
  • Open Access
45 Citations
6,462 Views
18 Pages

Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel

  • Apriliana Cahya Khayrani,
  • Hafizah Mahmud,
  • Aung Ko Ko Oo,
  • Maram H. Zahra,
  • Miharu Oze,
  • Juan Du,
  • Md Jahangir Alam,
  • Said M. Afify,
  • Hagar A. Abu Quora and
  • Masaharu Seno
  • + 8 authors

27 February 2019

Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes...

  • Review
  • Open Access
21 Citations
4,521 Views
15 Pages

8 October 2023

Rheumatoid arthritis (RA), osteoarthritis (OA), and gout are the most prevalent degenerative joint diseases (DJDs). The pathogenesis underlying joint disease in DJDs remains unclear. Considering the severe toxicities reported with anti-inflammatory a...

  • Article
  • Open Access
366 Views
26 Pages

CD44 Targeting of Cisplatin-Loaded Hyaluronic Acid-Modified Mesoporous Silica Nanoparticles for Lung Adenocarcinoma: Synthesis, Characterization, In Vitro and In Vivo Evaluation

  • Cem Güler,
  • S. Sacide Gelen,
  • Ebru Şancı,
  • Aylin Buhur,
  • H. Ece Tıkır,
  • Ayşe Nalbantsoy,
  • Adem Güner,
  • E. İlker Medine,
  • Altuğ Yavaşoğlu and
  • N. Ülkü Karabay Yavaşoğlu
  • + 1 author

Background/Objectives: Cisplatin (CDDP) is widely used in the treatment of non-small cell lung cancer (NSCLC); however, its clinical efficacy is limited by severe systemic toxicity. Hyaluronic acid (HA) modification enables the targeting of CD44-over...

  • Review
  • Open Access
2 Citations
3,246 Views
22 Pages

Despite the development of a wide plethora of different anticancer agents, most of them are not used for patient treatment due to adverse effects caused by untargeted cytotoxicity. To prevent this unwanted toxicity, it is necessary to develop therapi...

  • Article
  • Open Access
4 Citations
13,699 Views
15 Pages

Immunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5

  • Sandra Lüttgau,
  • Dorothée Deppe,
  • Saskia Meyer,
  • Regina Fertig,
  • Hossein Panjideh,
  • Martin Lipp,
  • Oliver Schmetzer,
  • Antonio Pezzutto,
  • Frank Breitling and
  • Gerhard Moldenhauer

14 May 2013

Using genetic engineering a humanized Fab fragment with specificity for CD19 was fused to a disulfide-stabilized single-chain antibody (dsFv) recognizing CD5. This format should show reduced immunogenicity and improved tissue penetration. The specifi...

  • Review
  • Open Access
90 Citations
12,845 Views
19 Pages

CD133, Selectively Targeting the Root of Cancer

  • Jörg U. Schmohl and
  • Daniel A. Vallera

28 May 2016

Cancer stem cells (CSC) are capable of promoting tumor initiation and self-renewal, two important hallmarks of carcinoma formation. This population comprises a small percentage of the tumor mass and is highly resistant to chemotherapy, causing the mo...

  • Article
  • Open Access
22 Citations
6,008 Views
21 Pages

Optimization of Liposomes for Antigen Targeting to Splenic CD169+ Macrophages

  • Maarten K. Nijen Twilhaar,
  • Lucas Czentner,
  • Joanna Grabowska,
  • Alsya J. Affandi,
  • Chun Yin Jerry Lau,
  • Katarzyna Olesek,
  • Hakan Kalay,
  • Cornelus F. van Nostrum,
  • Yvette van Kooyk and
  • Joke M.M. den Haan
  • + 1 author

Despite promising progress in cancer vaccination, therapeutic effectiveness is often insufficient. Cancer vaccine effectiveness could be enhanced by targeting vaccine antigens to antigen-presenting cells, thereby increasing T-cell activation. CD169-e...

  • Review
  • Open Access
48 Citations
10,829 Views
21 Pages

23 October 2020

CD123, the α chain of the interleukin 3 receptor, is a cytokine receptor that is overexpressed in multiple hematolymphoid neoplasms, including acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, acute lymphoblastic leukemia, h...

  • Article
  • Open Access
309 Views
18 Pages

CD25-Targeted Aptamer–Drug Conjugate for the Treatment of CD25-Expressing Hematological Malignancies

  • Sanghyeok Woo,
  • Ju-Hyung Kang,
  • Inu Song,
  • Soryong Lim,
  • Hwarim Ryu,
  • Yujin Lee and
  • Daekyun Lee

Background: CD25, the α-chain of the interleukin-2 (IL-2) receptor, is highly expressed on malignant cells and tumor-infiltrating regulatory T-cells (Tregs) in hematologic malignancies, making it an attractive therapeutic target for tumor elimi...

  • Review
  • Open Access
212 Citations
22,145 Views
31 Pages

Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases

  • Maria K. Skytthe,
  • Jonas Heilskov Graversen and
  • Søren K. Moestrup

The macrophage is a key cell in the pro- and anti-inflammatory response including that of the inflammatory microenvironment of malignant tumors. Much current drug development in chronic inflammatory diseases and cancer therefore focuses on the macrop...

  • Review
  • Open Access
36 Citations
7,222 Views
22 Pages

1 February 2023

In spite of consistent progress at the level of basic research and of clinical treatment, acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric patients. To improve the outcomes of these patients, it is necessar...

  • Review
  • Open Access
31 Citations
8,292 Views
22 Pages

6 April 2023

Tetraspanin CD81 plays major roles in cell-cell interactions and the regulation of cellular trafficking. This cholesterol-embarking transmembrane protein is a co-receptor for several viruses, including HCV, HIV-1 and Chikungunya virus, which exploits...

  • Article
  • Open Access
8 Citations
4,903 Views
14 Pages

Aptamer Targets Triple-Negative Breast Cancer through Specific Binding to Surface CD49c

  • Quanyuan Wan,
  • Zihua Zeng,
  • Jianjun Qi,
  • Yingxin Zhao,
  • Xiaohui Liu,
  • Zhenghu Chen,
  • Haijun Zhou and
  • Youli Zu

18 March 2022

Although targeted cancer therapy can induce higher therapeutic efficacy and cause fewer side effects in patients, the lack of targetable biomarkers on triple-negative breast cancer (TNBC) cells limits the development of targeted therapies by antibody...

  • Article
  • Open Access
13 Citations
5,796 Views
16 Pages

Engineering Modular Half-Antibody Conjugated Nanoparticles for Targeting CD44v6-Expressing Cancer Cells

  • Bianca N. Lourenço,
  • Rúben F. Pereira,
  • Cristina C. Barrias,
  • Claudia Fischbach,
  • Carla Oliveira and
  • Pedro L. Granja

23 January 2021

Gastric cancer (GC) remains a major cause of death worldwide mainly because of the late detection in advanced stage. Recently, we proposed CD44v6 as a relevant marker for early detection of GC, opening new avenues for GC-targeted theranostics. Here,...

  • Article
  • Open Access
1,803 Views
13 Pages

In Silico Exploration of CD200 as a Therapeutic Target for COVID-19

  • Vladimir Perovic,
  • Sanja Glisic,
  • Milena Veljkovic,
  • Slobodan Paessler and
  • Veljko Veljkovic

SARS-CoV-2, the pathogen causing COVID-19, continues to pose a significant threat to public health and has had major economic implications. Developing safe and effective vaccines and therapies offers a path forward for overcoming the COVID-19 pandemi...

  • Review
  • Open Access
29 Citations
12,807 Views
21 Pages

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance

  • Danilo De Novellis,
  • Raffaele Fontana,
  • Valentina Giudice,
  • Bianca Serio and
  • Carmine Selleri

30 December 2022

CD38 and B-cell maturation antigens (BCMAs) are prevalently expressed on neoplastic plasma cells in multiple myeloma (MM), making them ideal therapeutic targets. Anti-CD38 monoclonal antibodies, such as approved daratumumab and isatuximab, are curren...

  • Article
  • Open Access
30 Citations
8,882 Views
14 Pages

Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers

  • Yingnan Si,
  • Ya Zhang,
  • Jia-Shiung Guan,
  • Hanh Giai Ngo,
  • Angela Totoro,
  • Ajeet Pal Singh,
  • Kai Chen,
  • Yuanxin Xu,
  • Eddy S. Yang and
  • Xiaoguang (Margaret) Liu
  • + 2 authors

10 August 2021

Triple-negative breast cancers (TNBCs) are frequently recurrent due to the development of drug resistance post chemotherapy. Both the existing literature and our study found that surface receptor CD47 (cluster of differentiation 47) was upregulated i...

  • Review
  • Open Access
116 Citations
13,106 Views
17 Pages

CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker

  • Alexandra Landras,
  • Coralie Reger de Moura,
  • Fanelie Jouenne,
  • Celeste Lebbe,
  • Suzanne Menashi and
  • Samia Mourah

16 November 2019

Microenvironment plays a crucial role in tumor development and progression. Cancer cells modulate the tumor microenvironment, which also contribute to resistance to therapy. Identifying biomarkers involved in tumorigenesis and cancer progression repr...

  • Article
  • Open Access
6 Citations
4,672 Views
14 Pages

A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)

  • Jiashuai Zhang,
  • Zhuoxin (Zora) Zhou,
  • Kai Chen,
  • Seulhee Kim,
  • Irene Soohyun Cho,
  • Tanvi Varadkar,
  • Hailey Baker,
  • Ju Hwan Cho,
  • Lufang Zhou and
  • Xiaoguang (Margaret) Liu

30 September 2023

Non-small cell lung cancer (NSCLC) patients, accounting for approximately 85% of lung cancer cases, are usually diagnosed in advanced stages. Traditional surgical resection and radiotherapy have very limited clinical benefits. The objective of this s...

  • Article
  • Open Access
18 Citations
4,329 Views
21 Pages

Multifunctional, CD44v6-Targeted ORMOSIL Nanoparticles Enhance Drugs Toxicity in Cancer Cells

  • Lucía Morillas-Becerril,
  • Elektra Peta,
  • Luca Gabrielli,
  • Venera Russo,
  • Elisa Lubian,
  • Luca Nodari,
  • Maria Grazia Ferlin,
  • Paolo Scrimin,
  • Giorgio Palù and
  • Marta Trevisan
  • + 3 authors

10 February 2020

Drug-loaded, PEGylated, organic-modified silica (ORMOSIL) nanoparticles prepared by microemulsion condensation of vinyltriethoxysilane (VTES) were investigated as potential nanovectors for cancer therapy. To target cancer stem cells, anti-CD44v6 anti...

  • Article
  • Open Access
75 Citations
8,218 Views
26 Pages

Hyaluronic Acid-Decorated Chitosan Nanoparticles for CD44-Targeted Delivery of Everolimus

  • Enrica Chiesa,
  • Rossella Dorati,
  • Bice Conti,
  • Tiziana Modena,
  • Emanuela Cova,
  • Federica Meloni and
  • Ida Genta

Bronchiolitis obliterans syndrome (BOS), caused by lung allograft-derived mesenchymal cells’ abnormal proliferation and extracellular matrix deposition, is the main cause of lung allograft rejection. In this study, a mild one-step ionotropic ge...

  • Article
  • Open Access
4 Citations
3,645 Views
14 Pages

CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target

  • Marcel Mayer,
  • Lisa Nachtsheim,
  • Franziska Hoffmann,
  • Ferdinand von Eggeling,
  • Orlando Guntinas-Lichius,
  • Johanna Prinz,
  • Jens Peter Klußmann,
  • Alexander Quaas,
  • Christoph Arolt and
  • Philipp Wolber

12 August 2022

Advanced salivary gland carcinomas (SGC) often lack therapeutic options. Agents targeting CD138 have recently shown promising results in clinical trials for multiple myeloma and a preclinical trial for triple-negative breast cancer. Immunohistochemis...

  • Article
  • Open Access
1 Citations
1,372 Views
16 Pages

Advanced Detection and Therapeutic Monitoring of Atherosclerotic Plaque Using CD36-Targeted Lipid Core Probe

  • Tingting Gao,
  • Siqi Gao,
  • Maolin Qiao,
  • Chuanlong Lu,
  • Heng Wang,
  • Hongjiu Zhang,
  • Lizheng Li,
  • Shule Wang,
  • Ruijing Zhang and
  • Honglin Dong

Background: Atherosclerotic diseases, including coronary heart disease and cerebrovascular disease, are leading causes of morbidity and mortality worldwide. Atherosclerosis is a chronic vascular condition marked by the accumulation of lipid plaque wi...

  • Article
  • Open Access
5 Citations
5,389 Views
25 Pages

Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies

  • Nivesh K. Mittal,
  • Bivash Mandal,
  • Pavan Balabathula,
  • Saini Setua,
  • Dileep R. Janagam,
  • Leonard Lothstein,
  • Laura A. Thoma and
  • George C. Wood

Doxorubicin cardiotoxicity has led to the development of superior chemotherapeutic agents such as AD 198. However, depletion of healthy neutrophils and thrombocytes from AD 198 therapy must be limited. This can be done by the development of a targete...

  • Hypothesis
  • Open Access
16 Citations
6,193 Views
23 Pages

Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer

  • Tomas Koltai,
  • Stephan Joel Reshkin,
  • Tiago M. A. Carvalho and
  • Rosa A. Cardone

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. Present-day treatments have not shown real improvements in reducing the high mortality rate and the short survival of the disease. The average survival is less than 5% afte...

  • Article
  • Open Access
11 Citations
3,328 Views
21 Pages

CD163 Monoclonal Antibody Modified Polymer Prodrug Nanoparticles for Targeting Tumor-Associated Macrophages (TAMs) to Enhance Anti-Tumor Effects

  • Zun Yang,
  • Haijiao Li,
  • Wenrui Zhang,
  • Mingzu Zhang,
  • Jinlin He,
  • Zepeng Yu,
  • Xingwei Sun and
  • Peihong Ni

Tumor-associated macrophages (TAMs)-based immunotherapy is a promising strategy. Since TAMs are mainly composed of M2-type macrophages, they have a promoting effect on tumor growth, invasion, and metastasis. M2-type macrophages contain a specific rec...

  • Article
  • Open Access
20 Citations
5,014 Views
14 Pages

Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels

  • Maximilian Scherger,
  • Evangelia Bolli,
  • Ana Rita Pombo Antunes,
  • Sana Arnouk,
  • Judith Stickdorn,
  • Alexandra Van Driessche,
  • Hansjörg Schild,
  • Stephan Grabbe,
  • Bruno G. De Geest and
  • Lutz Nuhn
  • + 1 author

1 October 2020

To target nanomedicines to specific cells, especially of the immune system, nanobodies can be considered as an attractive tool, as they lack the Fc part as compared to traditional antibodies and, thus, prevent unfavorable Fc-receptor mediated mistarg...

  • Article
  • Open Access
46 Citations
11,359 Views
19 Pages

CD44-Targeted Carriers: The Role of Molecular Weight of Hyaluronic Acid in the Uptake of Hyaluronic Acid-Based Nanoparticles

  • Enrica Chiesa,
  • Antonietta Greco,
  • Federica Riva,
  • Rossella Dorati,
  • Bice Conti,
  • Tiziana Modena and
  • Ida Genta

17 January 2022

Nanotechnology offers advanced biomedical tools for diagnosis and drug delivery, stressing the value of investigating the mechanisms by which nanocarriers interact with the biological environment. Herein, the cellular response to CD44-targeted nanopa...

  • Review
  • Open Access
63 Citations
14,318 Views
24 Pages

Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs

  • Cristina Capuano,
  • Chiara Pighi,
  • Simone Battella,
  • Davide De Federicis,
  • Ricciarda Galandrini and
  • Gabriella Palmieri

20 May 2021

Natural killer (NK) cells hold a pivotal role in tumor-targeting monoclonal antibody (mAb)-based activity due to the expression of CD16, the low-affinity receptor for IgG. Indeed, beyond exerting cytotoxic function, activated NK cells also produce an...

  • Article
  • Open Access
3 Citations
2,713 Views
11 Pages

Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer

  • Isis Wolf,
  • Susanne Schultze-Seemann,
  • Christian Gratzke and
  • Philipp Wolf

9 January 2025

Background/Objectives: Photoimmunotherapy (PIT) is an innovative approach for the targeted therapy of cancer. In PIT, photosensitizer dyes are conjugated to tumor-specific antibodies for targeted delivery into cancer cells. Upon irradiation with visi...

  • Article
  • Open Access
12 Citations
3,814 Views
12 Pages

8 December 2018

Cadmium telluride (CdTe) films were deposited on glass substrates by direct current (DC) magnetron sputtering, and the effect of substrate-target distance (Dts) on properties of the CdTe films was investigated by observations of X-ray diffraction (XR...

  • Article
  • Open Access
9 Citations
4,637 Views
17 Pages

Triple-negative breast cancer (TNBC) is a highly aggressive subset of breast cancer with limited therapeutic options. However, its immune evasion mechanisms, characterized by the over-expression of the immune checkpoint molecules PD-L1 and CD47, can...

  • Review
  • Open Access
11 Citations
4,690 Views
15 Pages

Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia

  • Andrew H. Matthews,
  • Keith W. Pratz and
  • Martin P. Carroll

29 November 2022

After forty years of essentially unchanged treatment in acute myeloid leukemia (AML), innovation over the past five years has been rapid, with nine drug approvals from 2016 to 2021. Increased understanding of the molecular changes and genetic ontolog...

  • Article
  • Open Access
23 Citations
4,035 Views
20 Pages

CD44-Targeted Lipid Polymer Hybrid Nanoparticles Enhance Anti-Breast Cancer Effect of Cordyceps militaris Extracts

  • Jiraphong Suksiriworapong,
  • Nutthachai Pongprasert,
  • Somnuk Bunsupa,
  • Vincenzo Taresco,
  • Valentina Cuzzucoli Crucitti,
  • Thitapa Janurai,
  • Pornpoj Phruttiwanichakun,
  • Krisada Sakchaisri and
  • Amaraporn Wongrakpanich

This study aimed to improve the anticancer effect of Cordyceps militaris herbal extract (CME) on breast cancer cells with hyaluronic acid (HYA) surface-decorated lipid polymer hybrid nanoparticles (LPNPs) and evaluate the applicability of a synthesiz...

  • Article
  • Open Access
17 Citations
5,526 Views
18 Pages

Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease

  • Sébastien Gouard,
  • Catherine Maurel,
  • Séverine Marionneau-Lambot,
  • Delphine Dansette,
  • Clément Bailly,
  • François Guérard,
  • Nicolas Chouin,
  • Ferid Haddad,
  • Cyril Alliot and
  • Michel Chérel
  • + 3 authors

22 September 2020

Despite therapeutic progress in recent years with the introduction of targeted therapies (daratumumab, elotuzumab), multiple myeloma remains an incurable cancer. The question is therefore to investigate the potential of targeted alpha therapy, combin...

  • Article
  • Open Access
28 Citations
4,940 Views
27 Pages

Extracellular Vesicle Membrane Protein Profiling and Targeted Mass Spectrometry Unveil CD59 and Tetraspanin 9 as Novel Plasma Biomarkers for Detection of Colorectal Cancer

  • Srinivas Dash,
  • Chia-Chun Wu,
  • Chih-Ching Wu,
  • Sum-Fu Chiang,
  • Yu-Ting Lu,
  • Chien-Yuh Yeh,
  • Jeng-Fu You,
  • Lichieh Julie Chu,
  • Ta-Sen Yeh and
  • Jau-Song Yu

28 December 2022

Extracellular vesicles (EVs) are valuable sources for the discovery of useful cancer biomarkers. This study explores the potential usefulness of tumor cell-derived EV membrane proteins as plasma biomarkers for early detection of colorectal cancer (CR...

  • Article
  • Open Access
28 Citations
5,935 Views
17 Pages

Targeting Chondroitin Sulfate Reduces Invasiveness of Glioma Cells by Suppressing CD44 and Integrin β1 Expression

  • Yin-Hung Chu,
  • Wen-Chieh Liao,
  • Ying-Jui Ho,
  • Chih-Hsien Huang,
  • To-Jung Tseng and
  • Chiung-Hui Liu

20 December 2021

Chondroitin sulfate (CS) is a major component of the extracellular matrix found to be abnormally accumulated in several types of cancer tissues. Previous studies have indicated that CS synthases and modification enzymes are frequently elevated in hum...

  • Article
  • Open Access
13 Citations
3,235 Views
20 Pages

This study reports the CD44 receptor-targeted gold-doxorubicin nanocomposite (TGNC-DOX) for pulsatile chemo-photothermal therapy of triple-negative breast cancer (TNBC). The developed TGNC-DOX was nanometric, having a particle size of 71.34 ±...

  • Article
  • Open Access
8 Citations
3,815 Views
24 Pages

Synthesis, Formulation and Characterization of Immunotherapeutic Glycosylated Dendrimer/cGAMP Complexes for CD206 Targeted Delivery to M2 Macrophages in Cold Tumors

  • Marija Petrovic,
  • Alexandre Porcello,
  • Stoyan Tankov,
  • Oliwia Majchrzak,
  • Martin Kiening,
  • Annick Clara Laingoniaina,
  • Tayeb Jbilou,
  • Paul R. Walker,
  • Gerrit Borchard and
  • Olivier Jordan

Anti-tumor responses can be achieved via the stimulation of the immune system, a therapeutic approach called cancer immunotherapy. Many solid tumor types are characterized by the presence of immune-suppressive tumor-associated macrophage (TAMs) cells...

  • Article
  • Open Access
31 Citations
7,862 Views
15 Pages

Targeting Glioblastoma Cells Expressing CD44 with Liposomes Encapsulating Doxorubicin and Displaying Chlorotoxin-IgG Fc Fusion Protein

  • Hafizah Mahmud,
  • Tomonari Kasai,
  • Apriliana Cahya Khayrani,
  • Mami Asakura,
  • Aung Ko Ko Oo,
  • Juan Du,
  • Arun Vaidyanath,
  • Samah El-Ghlban,
  • Akifumi Mizutani and
  • Masaharu Seno
  • + 3 authors

26 February 2018

We recently have established a successful xenograft model of human glioblastoma cells by enriching hyaluronic acid-dependent spheroid-forming populations termed U251MG-P1 cells from U251MG cells. Since U251MG-P1 cells have been confirmed to express C...

  • Article
  • Open Access
1,429 Views
34 Pages

New Bioinformatic Insight into CD44: Classification of Human Variants and Structural Analysis of CD44 Targeting

  • Wiktoria A. Gerlicz,
  • Aleksandra Olczak,
  • Aneta M. Białkowska and
  • Aleksandra Twarda-Clapa

11 October 2025

The cluster of differentiation 44 (CD44) is a member of the hyaluronic acid (HA) receptor family of cell adhesion molecules. Besides HA, this transmembrane protein also serves as a receptor for other components of the extracellular matrix (ECM), incl...

  • Article
  • Open Access
8 Citations
6,363 Views
24 Pages

Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies

  • Rajbharan Yadav,
  • Siddharth Sukumaran,
  • Tanja S. Zabka,
  • Jinze Li,
  • Amy Oldendorp,
  • Gary Morrow,
  • Arthur Reyes,
  • Melissa Cheu,
  • Jessica Li and
  • Meric A. Ovacik
  • + 9 authors

The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to...

  • Article
  • Open Access
18 Citations
5,172 Views
18 Pages

Background: Human cell-secreted extracellular vesicles (EVs) are versatile nanomaterials suitable for disease-targeted drug delivery and therapy. Native EVs, however, usually do not interact specifically with target cells or harbor therapeutic drugs,...

  • Communication
  • Open Access
54 Citations
5,118 Views
16 Pages

23 January 2020

The presence of rare but highly tumorigenic cancer stem cells (CSCs) within the tumors is recognized as one of the major reasons of failure of conventional chemotherapies, mainly attributed to the development of drug resistance and increasing metasta...

  • Article
  • Open Access
12 Citations
3,446 Views
10 Pages

Tumor-Targeting Peptides Search Strategy for the Delivery of Therapeutic and Diagnostic Molecules to Tumor Cells

  • Maria D. Dmitrieva,
  • Anna A. Voitova,
  • Maya A. Dymova,
  • Vladimir A. Richter and
  • Elena V. Kuligina

30 December 2020

Background: The combination of the unique properties of cancer cells makes it possible to find specific ligands that interact directly with the tumor, and to conduct targeted tumor therapy. Phage display is one of the most common methods for searchin...

  • Review
  • Open Access
1 Citations
2,952 Views
14 Pages

11 July 2025

There have been multiple approved agents for relapsed/refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) over the last 8 years. The majority of these therapies act on specific signaling pathways in malignant B-cells. These signaling pathways stem...

  • Article
  • Open Access
41 Citations
6,178 Views
18 Pages

Hyaluronic Acid-Conjugated PLGA Nanoparticles Alleviate Ulcerative Colitis via CD44-Mediated Dual Targeting to Inflamed Colitis Tissue and Macrophages

  • Shwe Phyu Hlaing,
  • Jiafu Cao,
  • Juho Lee,
  • Jihyun Kim,
  • Aruzhan Saparbayeva,
  • Dongmin Kwak,
  • Hyunwoo Kim,
  • Seonghwan Hwang,
  • Hwayoung Yun and
  • Jin-Wook Yoo
  • + 2 authors

Although various local anti-inflammatory therapies for ulcerative colitis have been developed, rapid drug elimination from inflamed colitis tissue and off-target side effects reduce their therapeutic efficacy. In this study, we synthesized curcumin (...

  • Review
  • Open Access
40 Citations
7,508 Views
18 Pages

The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy

  • Yu Jun Wo,
  • Adelia Shin Ping Gan,
  • Xinru Lim,
  • Isabel Shu Ying Tay,
  • Sherlly Lim,
  • Jeffrey Chun Tatt Lim and
  • Joe Poh Sheng Yeong

20 December 2019

The tumor microenvironment (TME) consists of extracellular matrix proteins, immune cells, vascular cells, lymphatics and fibroblasts. Under normal physiological conditions, tissue homeostasis protects against tumor development. However, under patholo...

  • Article
  • Open Access
30 Citations
5,049 Views
18 Pages

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome

  • Mohammad Houshmand,
  • Francesca Garello,
  • Rachele Stefania,
  • Valentina Gaidano,
  • Alessandro Cignetti,
  • Michela Spinelli,
  • Carmen Fava,
  • Mahin Nikougoftar Zarif,
  • Sara Galimberti and
  • Giuseppe Saglio
  • + 14 authors

15 March 2021

CML is a hematopoietic stem-cell disorder emanating from breakpoint cluster region/Abelson murine leukemia 1 (BCR/ABL) translocation. Introduction of different TKIs revolutionized treatment outcome in CML patients, but CML LSCs seem insensitive to TK...

  • Article
  • Open Access
7 Citations
4,285 Views
16 Pages

21 January 2019

Background: CD34+ Endothelial Progenitor Cells (EPCs) play an important role in the recovery of injured endothelium and contribute to atherosclerosis (ATH) pathogenesis. Previously we described a potential atherogenic role for miR-125 that we aimed t...

of 115